The global critical limb ischemia treatment market is driven by rise in prevalence of critical limb ischemia. Growth of the market is also attributed to increase in awareness about critical limb ischemia and rich product pipeline.
Critical limb ischemia (CLI) is a severe peripheral arterial disease (PAD), wherein chronic inflammation associated with atherosclerosis (progressive thickening of arteries lining) causes reduced blood flow to the extremities (legs, feet, and hands), leading to severe pain and ulcers or sore. Major risk factors for critical limb ischemia comprise aging (people aged 60 or over are at high risk of developing this diseased condition), obesity, diabetes, high cholesterol level, smoking, sedentary lifestyle, and high blood pressure. Critical limb ischemia is associated with symptoms such as ischemic rest pain, gangrene, or tissue loss. Rise in prevalence of critical limb ischemia is anticipated to increase demand for therapeutics, which in turn is expected to drive the global critical limb ischemia treatment market. According to recent study, around 2 million to 3 million people suffer from critical limb ischemia in the U.S. Moreover, increase in health care expenditure and rise in the number of clinical trials are likely to propel the global critical limb ischemia treatment market.
critical limb ischemia treatment market
The global critical limb ischemia treatment market has been segmented based on treatment and region. In terms of treatment, the global market has been classified into devices and medications. The devices segment accounted for major share of the global market in terms of revenue in 2018. The segment is projected to expand at a high CAGR during the forecast period due to increase in demand for various type of stents and balloons in the treatment of critical limb ischemia. The devices segment has been categorized into embolic protection devices and peripheral dilatation systems. The peripheral dilatation systems segment dominated the devices segment in 2018, as dilation devices and stents provide dilation effectively and protect the artery wall. These devices are the most frequently used treatments for critical limb ischemia and provide certain advantage over traditional treatments. The peripheral dilatation systems segment has been bifurcated into balloon dilators and vascular stents. The vascular stents segment dominated the global market in 2018. The trend is likely to continue during the forecast period. The medications segment includes antiplatelet drugs, antihypertensive agents, lipid-lowering agents, antithrombotic agents, and others.
In terms of region, the global critical limb ischemia treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2018 and is projected to gain market share from 2019 to 2027. The market in North America is driven by increase in incidence of critical limb ischemia, new product approvals, strong product pipeline, and rise in health care expenditure. The critical limb ischemia treatment market in Asia Pacific is anticipated to grow at a rapid pace during the forecast period. Japan dominated the market in the region in 2018 due to high population of patients with critical limb ischemia.
Major players operating in the global critical limb ischemia treatment market include Medtronic plc, Boston Scientific Corporation, Cesca Therapeutics, Inc., Abbott Laboratories, Pluristem Therapeutics, Inc., Rexgenero Ltd., LimFlow SA, Micro Medical Solutions, and Cardiovascular Systems, Inc. These companies have adopted the strategy of acquisition and collaboration to strengthen their positions in the global market.
Focus on Optimal Revascularization Strategies to Benefit Patients Critical Limb Ischemia Treatment Market
The critical limb ischemia (CLI) treatment market has grown in outlook from the growing adoption of promising therapeutic strategies for its management. CLI is considered as an advanced stage of peripheral artery disease (PAD). It is known to cause limb loss and adverse cardiovascular events in a short time. The association of CLI with significant comorbidities has intensified the need for constantly improving the endovascular techniques. Advances made in arterial revascularization have been propelled by the advent of new approaches for non-invasive treatment. The adoption of optimal revascularization strategies is a key trend that is expected to bolster the revenue prospects of the critical limb ischemia (CLI) treatment market. Along with this, there is a high need for optimizing various cardiovascular risk factors to improve the outcomes of recently developed treatments in the market. In this regard, ongoing research in gene and cell-based therapies are expected to expand the horizon for industry players in the critical limb ischemia (CLI) treatment market. The high economic burden of CLI in the developing world is expected to underpin substantial demand coming from these regions. The major risks such as myocardial infarction, stroke, and death of PAD also translates to CLI, thereby propelling the need for multiple treatment strategies.
The Covid-19 pandemic proves to be one of the major concerns of governments of almost all nations across the globe. This is despite the fact a large part of the populations in some regions have been vaccinated with all the required jabs. The scarce understanding of the epidemiology and etiology of the disease is a key factor that has constrained the advent of effective therapeutic options. However, with the recent advent of a few vaccines getting emergency market authorisation in numerous key economies has created an air of optimism for economic growth. The successful immunization in some countries has resulted in substantially reducing the morbidity as well as mortality in recent months. All these macroeconomic trends are also likely to impact the dynamics of the critical limb ischemia (CLI) treatment market.
The global critical limb ischemia treatment market has been segmented as below: